Literature DB >> 10697594

Tumor stroma.

R Seljelid1, S Jozefowski, B Sveinbjörnsson.   

Abstract

The accumulated evidence indicates that tumor stroma with its cells and cell products plays a much more active and important role than previously believed. Growth factors and cytokines produced by macrophages and other cells are crucial for stroma formation and angiogenesis. Lytic enzymes provided by stromal cells may be essential for invasion. TNF and other inflammatory mediators may be operative in the systemic effects of tumors, e.g. cachexia. All these effects may come about through the action of soluble substances produced by tumor cells or by more intimate interactions. There is no evidence that stromal cells are directly involved in carcinogenesis--i.e. the cellular transformation to produce the malignant cell. On the other hand, stromal cells and other components of the interstitia are instrumental in tumorigenesis--i.e. the development of a real malignant tumor from its start on the cellular or subcellular level. In one way of looking at it, the stromal cells, e.g. macrophages may be considered as "slaves", kept to carry out certain functions, synthesize essential substances e.g. growth factors that the tumor cells do not have the capacity or the degree of finely tuned machinery to produce. The objective of immunomodulation should then be to create a "slave uprising", to make the macrophages and other cells turn against their masters, stop producing growth factors and start producing harmful factors that would lead to the elimination of the malignant growth. The first target of immunomodulation in tumor disease should probably be local malignancies where no effective treatment exists today- and selected cases of metastatic prevention (181, 182).

Entities:  

Mesh:

Year:  1999        PMID: 10697594

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  10 in total

1.  Changes in vascularization in substantia nigra pars compacta of monkeys rendered parkinsonian.

Authors:  C Barcia; V Bautista; A Sánchez-Bahillo; E Fernández-Villalba; B Faucheux; M Poza y Poza; A Fernandez Barreiro; E C Hirsch; M-T Herrero
Journal:  J Neural Transm (Vienna)       Date:  2005-01-24       Impact factor: 3.575

2.  Improved correlation of histological data with DCE MRI parameter maps by 3D reconstruction, reslicing and parameterization of the histological images.

Authors:  Fabian Kiessling; Martin Le-Huu; Tobias Kunert; Matthias Thorn; Silvia Vosseler; Kerstin Schmidt; Johannes Hoffend; Hans-Peter Meinzer; Norbert E Fusenig; Wolfhard Semmler
Journal:  Eur Radiol       Date:  2005-03-04       Impact factor: 5.315

3.  Viable head and neck tumor spheroids stimulate in vitro autologous monocyte MCP-1 secretion through soluble substances and CD14/lectin-like receptors.

Authors:  Carla Olsnes; John-Helge Heimdal; Kenneth W Kross; Jan Olofsson; Hans Jørgen Aarstad
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-11-19       Impact factor: 2.503

4.  The shed ectodomain of type XIII collagen associates with the fibrillar fibronectin matrix and may interfere with its assembly in vitro.

Authors:  Marja-Riitta Väisänen; Timo Väisänen; Hongmin Tu; Päivi Pirilä; Raija Sormunen; Taina Pihlajaniemi
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

5.  The prognostic relevance of angiogenesis and mast cells in squamous cell carcinoma of the oesophagus.

Authors:  G O Elpek; T Gelen; N H Aksoy; A Erdoğan; L Dertsiz; A Demircan; N Keleş
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

6.  Colorectal cancer cells activate adjacent fibroblasts resulting in FGF1/FGFR3 signaling and increased invasion.

Authors:  Maria L Henriksson; Sofia Edin; Anna M Dahlin; Per-Arne Oldenborg; Åke Öberg; Bethany Van Guelpen; Jörgen Rutegård; Roger Stenling; Richard Palmqvist
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

Review 7.  Parkinson's disease and inflammatory changes.

Authors:  Carlos Barcia; Andrés Fernández Barreiro; Máximo Poza; María-Trinidad Herrero
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.911

8.  Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer.

Authors:  Nichole R Dean; J Robert Newman; Emily E Helman; Wenyue Zhang; Seena Safavy; D M Weeks; Mark Cunningham; Linda A Snyder; Yi Tang; Li Yan; Lacey R McNally; Donald J Buchsbaum; Eben L Rosenthal
Journal:  Clin Cancer Res       Date:  2009-06-09       Impact factor: 12.531

9.  Cell adhesion to the extracellular matrix protein fibronectin modulates radiation-dependent G2 phase arrest involving integrin-linked kinase (ILK) and glycogen synthase kinase-3beta (GSK-3beta) in vitro.

Authors:  N Cordes; D van Beuningen
Journal:  Br J Cancer       Date:  2003-05-06       Impact factor: 7.640

10.  Loss of Endocan tumorigenic properties after alternative splicing of exon 2.

Authors:  Florence Depontieu; Bogdan-Dragos Grigoriu; Arnaud Scherpereel; Estelle Adam; Maryse Delehedde; Philippe Gosset; Philippe Lassalle
Journal:  BMC Cancer       Date:  2008-01-18       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.